NVAX Jan 2025 12.500 call
| Previous Close | 3.2900 |
| Open | 2.8100 |
| Bid | 2.6300 |
| Ask | 2.7600 |
| Strike | 12.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 2.7000 - 2.8100 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 1.75k |
GuruFocus.comNovavax Inc (NVAX) Q2 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
Novavax Inc (NVAX) reports significant revenue from Sanofi partnership and outlines strategic shifts to enhance future growth potential.
PR NewswireNovavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the European Commission granted Marketing Authorization for Novavax's updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2705), dispersion for injection, for use in individuals aged 12 and older for the prevention of COVID-19 in the European Union (EU). This decision follows the positive opinion from the Committee for Medicinal Products fo
ZacksNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
